Nichi-Iko Looks To File For Interchangeable Infliximab In US Next Year

 
• By Aidan Fry

With a US filing for interchangeable infliximab scheduled for next year, Nichi-Iko is lining up a launch of etanercept in Japan as it seeks alliances to broaden its biosimilars pipeline.  

TrainTracks
Achieving An Interhangeability Designation For Infliximab Would Allow Pharmacy-Level Switching To Nichi-Iko's Infliximab In The US • Source: Shutterstock

More from Biosimilars

More from Products